Goodwill and Intangible Assets	12 Months Ended
Goodwill and Intangible Assets	Dec. 31, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill And Intangible Assets Disclosure [Text Block]	Note 16 – Goodwill and Other Intangible Assets Changes in the carrying amount of goodwill for the years ended December 31, 2020 and 2019 were as follows: Global Specialty Americas EMEA Asia/Pacific Businesses Total Balance as of December 31, 2018 $ 28,464 $ 17,423 $ 13,149 $ 24,297 $ 83,333 Goodwill additions 188,494 114,167 130,091 91,545 524,297 Currency translation adjustments (573) 1,428 (1,513) 233 (425) Balance as of December 31, 2019 216,385 133,018 141,727 116,075 607,205 Goodwill additions 1,485 531 — 1,329 3,345 Currency translation and other adjustments (4,628) 6,613 16,363 2,314 20,662 Balance as of December 31, 2020 $ 213,242 $ 140,162 $ 158,090 $ 119,718 $ 631,212 Other adjustments in the table above includes updates to the Company’s allocation of the Houghton purchase price and associated goodwill to each of the Company’s reportable segments during the year ended December 31, 2020, including a $ 2.6 million decrease in the Americas, a $ 1.4 million decrease in EMEA, a $ 8.0 million increase in Asia/Pacific and a $ 0.5 million increase in Global Specialty Businesses. Gross carrying amounts and accumulated amortization for definite-lived intangible assets as of December 31, 2020 and 2019 were as follows: Gross Carrying Accumulated Amount Amortization 2020 2019 2020 2019 Customer lists and rights to sell $ 839,551 $ 792,362 $ 99,806 $ 49,932 Trademarks, formulations and product technology 166,448 157,049 30,483 21,299 Other 6,372 6,261 5,824 5,776 Total definite -lived intangible assets $ 1,012,371 $ 955,672 $ 136,113 $ 77,007 The Company recorded $ 55.9 million, $ 26.7 million and $ 7.3 million of amortization expense during the years ended December 31, 2020, 2019 and 2018, respectively. Amortization is recorded within SG&A in the Company’s Consolidated Statements of Income. Estimated annual aggregate amortization expense for the subsequent five years is as follows: For the year ended December 31, 2021 $ 58,752 For the year ended December 31, 2022 58,590 For the year ended December 31, 2023 58,361 For the year ended December 31, 2024 57,935 For the year ended December 31, 2025 57,263 The Company has four indefinite-lived intangible assets totaling $ 205.1 million as of December 31, 2020, including $ 204.0 million of indefinite-lived intangible assets for trademarks and tradename associated with the Combination. Comparatively, the Company had four indefinite-lived intangible assets for trademarks and tradename totaling $ 243.1 million as of December 31, 2019. The Company completes its annual goodwill and indefinite -lived intangible asset impairment test during the fourth quarter of each year, or more frequently if triggering events indicate a possible impairment in one or more of its reporting units. The Company completed its annual impairment assessment during the fourth quarter of 2020 and concluded no impairment charge was warranted. The Company continually evaluates financial performance, economic conditions and other relevant developments in assessing if an interim period impairment test for one or more of its reporting units is necessary. As of March 31, 2020, the Company evaluated the initial impact of COVID-19 on the Company’s operations, and the volatility and uncertainty in the economic outlook as a result of COVID-19 to determine if they indicated it was more likely than not that the carrying value of any of the Company’s reporting units or indefinite-lived or long-lived assets was not recoverable. The Company concluded that the impact of COVID-19 did not represent a triggering event as of March 31, 2020 with regards to the Company’s reporting units or indefinite-lived and long-lived assets, except for the Company’s Houghton and Fluidcare trademarks and tradename indefinite-lived intangible assets. The determination of estimated fair value of the Houghton and Fluidcare trademarks and tradename indefinite-lived assets was based on a relief from royalty valuation method which requires management’s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to the weighted average cost of capital (“WACC”) and royalty rates, as well as revenue growth rates and terminal growth rates. In the first quarter of 2020, as a result of the impact of COVID-19 driving a decrease in projected legacy Houghton net sales in the current year and the impact of the current year decline on projected future legacy Houghton net sales as well as an increase in the WACC assumption utilized in the quantitative impairment assessment, the Company concluded that the estimated fair values of the Houghton and Fluidcare trademarks and tradename intangible assets were less than their carrying values. As a result, an impairment charge of $ 38.0 million, primarily related to the Houghton trademarks and tradename, to write down the carrying values of these intangible assets to their estimated fair values was recorded in the first quarter of 2020. As of December 31, 2020, the Company continued to evaluate the on-going impact of COVID-19 on the Company’s operations, and the volatility and uncertainty in the economic outlook as a result of COVID-19, to determine if this indicated it was more likely than not that the carrying value of any of the Company’s reporting units or indefinite-lived or long-lived intangible assets were not recoverable. The Company concluded that the impact of COVID-19 did not represent a triggering event as of December 31, 2020 with regards to any of the Company’s reporting units or indefinite-lived and long-lived intangible assets. While the Company concluded that the impact of COVID-19 did not represent a triggering event as of December 31, 2020 for any of its other long-lived or indefinite-lived assets or reporting units, the Company will continue to evaluate the impact of COVID-19 on the Company’s current and projected results. If the current economic conditions worsen or projections of the timeline for recovery are significantly extended, then the Company may conclude in the future that the impact from COVID-19 requires the need to perform further interim quantitative impairment tests, which could result in additional impairment charges in the future.